Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy

Developmental Medicine and Child Neurology

Volumn 51, Issue 6, 2009, Pages 436-445

  Kaňovský, Petr ^a,d,e   Bareš, Martin ^a   Severa, Stanislav ^b   Richardson, Alan ^c   Kraus, J ^e   Severa, S ^e   Turconi, A C ^e   Bonikowski, M ^e   Jasinski, M ^e   Jozwiak, M ^e   Lukaszewska, A ^e   Tymecka Maciag, I ^e   Wendorff, J ^e   Benetin, J ^e   Lisy L ^e   Cardo, E ^e   Macaya, A ^e   Pascual, S I P ^e   Poo, P ^e   Fontan, D ^e   Morton, R ^e   more..

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b Regional Hospital   (Czech Republic)

^c IPSEN   (France)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ARTICLE; BRONCHITIS; CEREBRAL PALSY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; GASTROCNEMIUS MUSCLE; HUMAN; INFECTION; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CONTRACTURE; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RHINITIS; SINGLE BLIND PROCEDURE; SPASTICITY; VIRUS INFECTION;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; CONTRACTURE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAIT; HUMANS; INFANT; LEG; MALE; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; TRAUMA SEVERITY INDICES; TREATMENT OUTCOME;

EID: 65549158884     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2008.03264.x     Document Type: Article

References (27)

1. Hagberg B, Hagberg G. Origins of cerebral palsy. In: David TJ, editor. Recent advances in paediatrics, No. 11, London: Churchill Livingston, 1999: 67-83.
2. Albright AL. Spastic cerebral palsy: Approaches to drug treatment. CNS Drugs 1995; 4: 17-27.
3. Young R. Spasticity: A review. Neurology 1994; 44 (Suppl 9): S12-20.
4. Boyd R, Graham HK. Botulinum toxin type a in the managements of children with cerebral palsy: Indications and outcome. Eur J Neurol 1997; 4: S15-22.
5. Gage JR. Gait analysis in cerebral palsy. Clinics in Developmental Medicine No. 121. London: Mac Keith Press, 1991.
6. Morton RE, Hankinson J, Nicholson J. Botulinum toxin for cerebral palsy; where are we now? Arch Dis Child 2004; 89: 1133-37.
7. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160-63.
8. Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994; 36: 379-85.
9. Baker R. Botulinum toxin A (Dysport) for the treatment of dynamic equinus spasticity associated with cerebral palsy: Results of double-blind, placebo-controlled, dose-ranging study. Gait Posture 2000; 12: 64-65.
10. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: A randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44: 666-75.
11. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 481-87.
12. Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: A randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006; 48: 10-13.
13. Kaňovský P, Bareš M, Severa S, et al. Functional benefit of botulinum toxin (Dysport ®) in the treatment of dynamic equinus cerebral palsy spasticity: A prospective, multicentre, double-blind, placebo-controlled study. Česk Slov Neurol Neurochir 2004; 67: 16-23.
14. Watkins B, Darrah J, Pain K. Reliability of passive ankle dorsiflexion measurements in children: Comparison of universal and biplane goniometers. Pediatr Phys Ther 1995; 7: 3-8.
15. Schoenfeld D. Partial residual estimation for the proportional hazards regression. Biometrika 1982; 69: 239-41.
16. Barry MJ. Physical therapy interventions for patients with movement disorders due to cerebral palsy. J Child Neurol 1996; 11(Suppl 1): S51-60.
17. Johnson DC, Damiano DL, Abel MF. The evolution of gait in childhood and adolescent cerebral palsy. J Pediatr Orthop 1997; 17: 392-96.
18. Norlin R, Odenrick P. Development of gait in spastic children with cerebral palsy. J Pediatr Orthop 1986; 6: 674-80.
19. Morton RE, Scott B, McClelland V, Henry A. Dislocation of the hips in children with bilateral spastic cerebral palsy, 1985-2000. Dev Med Child Neurol 2006; 48: 555-58.
20. Hagglund G, Andersson S, Duppe H, Lauge-Pedersen H, Nordmark E, Westbom L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: Results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 2005; 14: 269-73.
21. Gooch JL, Patton CP. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004; 85: 1121-24.
22. Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 2006; 88: 161-70.
23. Ruiz FJ, Guest JF, Lehmann A, et al. Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany. Eur J Health Econ 2004; 5: 227-35.
24. Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000; 11: 67-79.
25. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. J Neurol 1999; 246: 265-74.
26. Herrmann J, Mall V, Bigalke H. Neutralising antibodies and secondary non response in treatment of cerebral palsy with botulinum neurotoxin. (Presented at the Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine, 2000).
27. Molenberghs G. Editorial: What to do with missing data ? J Roy Stat Soc Series A (Statistics in Society) 2007; 170: 861-63.